儿童青少年及年轻成人女性癌症幸存者治疗相关生育损伤的剂量效应关系:PanCareLIFE欧洲病例对照研究
该病例对照研究嵌套于PanCareLIFE队列,纳入1332名女性儿童青少年及年轻成人癌症5年幸存者(450例生育损伤,882例匹配对照),评估化疗药物和放疗部位与生育损伤的剂量效应关系。结果显示环磷酰胺等效剂量>7121 mg/m2时生育损伤风险显著增加(OR=2.6,95%CI 1.9-3.6,P<0.001),白消安、下腹部放疗和全身照射在任何剂量下均与生育损伤相关。
要点
- 环磷酰胺等效剂量>7121 mg/m2者生育损伤风险显著增加(OR=2.6,95%CI 1.9-3.6)。
- 白消安、下腹部放疗和全身照射在任何剂量下均与生育损伤相关。
- 美法仑>140 mg/m2和丙卡巴肼>5600 mg/m2时提示性腺毒性。
核心结论
- 环磷酰胺等效剂量>7121 mg/m2与生育损伤风险显著增加相关(OR=2.6,95%CI 1.9-3.6,P<0.001)。
- 白消安、下腹部放疗和全身照射在任何剂量下均与生育损伤相关。
- 美法仑在>140 mg/m2、丙卡巴肼在>5600 mg/m2时提示性腺毒性。
研究设计与样本
- 病例对照研究嵌套于PanCareLIFE队列研究,来自8个国家、9个机构、11个队列。
- 共纳入1332名女性儿童青少年及年轻成人癌症5年幸存者,其中450例生育损伤者和882例匹配对照。
- 生育损伤定义综合问卷数据(原发性或继发性闭经、使用辅助生殖技术、未实现的生育意愿)和激素数据(FSH和AMH)。
- 采用多变量逻辑回归模型分析烷化剂暴露及个体化疗药物和放疗部位剂量分类的效应。
主要发现
- 环磷酰胺等效剂量评分与生育损伤呈正剂量效应关系,评分>7121 mg/m2者风险显著增加(OR=2.6,95%CI 1.9-3.6,P<0.001)。
- 以下治疗的累积剂量变量与生育损伤显著相关:白消安、卡莫司汀、环磷酰胺、美法仑、丙卡巴肼、下腹部放疗和全身照射。
- 白消安、下腹部放疗和全身照射似乎在任何剂量下均与生育损伤相关。
- 美法仑在中等/高剂量(>140 mg/m2)时提示性腺毒性。
- 丙卡巴肼在高剂量(>5600 mg/m2)时提示性腺毒性。
关键数值与推荐
- 环磷酰胺等效剂量>7121 mg/m2与生育损伤风险显著增加相关(OR=2.6,95%CI 1.9-3.6,P<0.001)。
- 美法仑剂量>140 mg/m2时提示性腺毒性。
- 丙卡巴肼剂量>5600 mg/m2时提示性腺毒性。
- 白消安、下腹部放疗和全身照射在任何剂量下均与生育损伤相关。
临床怎么用
- 识别生育损伤高风险幸存者,其生殖寿命可能缩短甚至缺失。
- 对即将开始抗癌治疗的女孩和年轻女性以及成年女性幸存者,应进行未来生育咨询。
- 如有意愿,将患者转诊至生殖专科医生进行生育力保存。
局限性
- 研究可能受到选择偏倚影响,因仅获得约一半原始基础队列的数据。
- 选择偏倚可能影响研究结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Which chemotherapeutic agents and body site-specific radiation fields are dose-dependently associated with an increased risk of fertility impairment in long-term female childhood, adolescent and young adulthood (CAYA) cancer survivors? SUMMARY ANSWER: Busulfan, lower abdominal radiotherapy (RT) and total body irradiation (TBI) seem to be associated with fertility impairment at any dose, whereas gonadotoxicity of melphalan and procarbazine is suggested at medium/high (>140 mg/m2) or high dose (>5600 mg/m2) therapy, respectively. WHAT IS KNOWN ALREADY: Several treatment-related fertility deficits, as assessed by both self-reported outcomes and hormonal markers are known to occur following treatment of CAYA cancer. However, knowledge regarding precise dose-related estimates of these treatment-related risks are scarce. STUDY DESIGN, SIZE, DURATION: The current case-control study was nested within the PanCareLIFE cohort study. In total, 1332 CAYA survivors from 8 countries, 9 institutions and 11 cohorts, participated in and contributed data to the study. PARTICIPANTS/MATERIALS, SETTING, METHODS: All participants were female 5-year CAYA cancer survivors. In total, 450 cases (fertility impaired survivors) and 882 matched controls (not fertility impaired survivors) were included. Fertility impairment was defined using both questionnaire data (primary or secondary amenorrhea; use of artificial reproductive techniques; unfulfilled wish to conceive) and hormonal data (FSH and anti-Müllerian hormone (AMH)). Multivariable logistic regression models were used to investigate the effect of (i) alkylating agent exposure, and (ii) dose categories for individual chemotherapeutic agents and for RT-exposed body sites. MAIN RESULTS AND THE ROLE OF CHANCE: A positive dose-effect relationship between cyclophosphamide equivalent dose (CED) score and fertility impairment was found, with survivors with a CED score > 7121 mg/m2 being at a significantly increased risk of fertility impairment (odds ratio (95% CI) = 2.6 (1.9-3.6) P < 0.001). Moreover, cumulative dose variables of the following treatments were significantly associated with fertility impairment: busulfan, carmustine, cyclophosphamide, melphalan, procarbazine, lower abdominal RT and TBI. Busulfan, lower abdominal RT and TBI seem to be associated with fertility impairment at any dose, whereas gonadotoxicity of melphalan and procarbazine is suggested at medium/high (>140 mg/m2) or high dose (>5600 mg/m2) therapy, respectively. LIMITATIONS, REASONS FOR CAUTION: Our study may have been subject to selection bias since data from about half of the original base cohorts were available for the current study. This could impact the generalizability of our study results. WIDER IMPLICATIONS OF THE FINDINGS: We identified survivors at high risk for fertility impairment and, consequently, for a reduced or even absent reproductive life span. Both girls and young women who are about to start anti-cancer treatment, as well as adult female survivors, should be counselled about future parenthood and referred to a reproductive specialist for fertility preservation, if desired. STUDY FUNDING/COMPETING INTEREST(S): This study has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 602030. There are no competing interests. TRIAL REGISTRATION NUMBER: n/a.
引用
- van den Berg MH, van Dijk M, Byrne J, et al. Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE). Hum Reprod. 2021. PMID: 33744927. doi:10.1093/humrep/deab035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。